Skip to Main Content

Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19

Conditions

Diseases of the Respiratory Systems | COVID-19 Inpatient

Phase COVID-II-III

What is the purpose of this trial?

Brief Summary:

Phase 2:

The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with severe COVID-19.

Phase 3:

The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with severe or critical COVID-19.

  • Trial with
    Regeneron Pharmaceuticals, Inc.
  • Start Date
    03/25/2020
  • End Date
    03/15/2021
Trial Image

For more information about this study, contact:

Nicole Grant

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    03/30/2020
  • Study HIC
    #2000027737